Dystonia Drugs Market by Drug Type (Anticonvulsants drugs, Others, Dopaminergic agents and GABAergic agents), Route of Administration (Oral and Injectable), Distribution Channel (Hospital Pharmacies, Online Providers and Drug Stores and Retail Pharmacies) and Geography (North America, Europe, APAC and RoW) - Forecast up to 2027
Dystonia can be referred to a movement disorder featured by involuntary muscle contractions which cause slow repetitive movements or abnormal postures. These muscle contractions result in unusual muscle movements and body postures. There are various types of dystonia affecting a single muscle, or a group of muscles or may affect muscles all over the body. The rise of the dystonia drugs market is projected to be driven by high potential in untapped, rising markets, owing to availability of developing healthcare infrastructure, rise in unmet healthcare needs, and rise in demand for advanced healthcare facilities. Additionally, surge in prevalence of dystonia and also surge in incidence of other neurological disorders having dystonia symptoms is propelling the growth of the market. This increase in incidence of dystonia, augments the demand for dystonia treatment medications which further accelerates the growth of the dystonia drugs market share. However, the huge costs incurred in the treatment of dystonia may limit the market growth. The Dystonia Drugs Market is anticipated to grow at a rate of 5.3% CAGR by 2027.
Dystonia Drugs Market by Drug Type
Anticonvulsants drugs
Others
Dopaminergic agents
GABAergic agents
Dystonia Drugs Market by Route of Administration
Oral
Injectable
Dystonia Drugs Market by Distribution Channel
Hospital Pharmacies
Online Providers
Drug Stores and Retail Pharmacies
Dystonia Drugs Market by Geography
North America
Europe
Asia Pacific
Rest of the World
The market based product type is divided into Anticonvulsants drugs, Others, Dopaminergic agents and GABAergic agents. GABAergic agents segment has the largest share in the market. The growth is ascribed to its advantages in treating dystonia, especially cervical dystonia. Moreover, the discovery of highly effective and potent GABAergic agent pharmaceuticals for treating dystonia, along with its more extensive prescription by healthcare experts, is boosting the segment's growth in the forecasted period.
As per the market by route of administration, the market is bifurcated into Oral and Injectable. Among them the injectable segment has the substantial share in the market. This is due to the increase in innovations in parenteral dosing and increased research and development for botulinum injections. Absorption of the medication, particularly aqueous solutions, is rapid and uniform. There is a swift commencement of effect compared to the oral and subcutaneous methods.
The distribution channel segment is classified into Hospital Pharmacies, Online Providers and Drug Stores and Retail Pharmacies. The drug stores & retail pharmacies segment is accounted for the maximum share in the market. This is because of its substantial chain of distribution networks and it being the oldest and most easy channel for providing drugs to consumers. Retail pharmacists prepare and dispense drugs, advise consumers on the proper use of medications, and inform them of possible drug interactions.
In market by geographical analysis, the North America region has acquired a substantial share in the market. The surge in incidences of dystonia coupled with surge in prevalence of other neurological conditions causing dystonia in U.S. population and other major nations is the key factor for augmenting demand for dystonia drugs in North America.
The federal government influences private investment on research and development through programs which augment the demand for prescription drugs, through policies (such as investment for basic research and regulations on what must be demonstrated in clinical trials) which affect the supply of new medicines, and through policies (such as vaccine recommendations) which affect both supply and demand. The surging R&D in the pharmaceutical industry worldwide is likely to improve the effectiveness of dystonia drugs and their utilization, thereby fueling the global market growth.
This report includes the key vendors operating in the market- Teva Pharmaceuticals Industries Ltd., F.Hoffmann-La Roche Ltd., Merz Pharma GmbH & Co. KGaA, Ipsen Pharma Biotech SAS, Hameln Pharma Gmbh (Siegfried Group, LLP), AbbVie, Inc., Amneal Pharmaceuticals, Inc., Wellona Pharma, Pfizer, Inc. and Novartis AG.
Henceforth, the dystonia drugs market is anticipated to witnessing a significant in the estimated time span. Since, compared to all treatments the drugs are considered to be the best option for the dystonia. The drugs are deemed to provide the quick and complete relief for the ailment.
This report of Dystonia Drugs market depicts the geographical regions and sub segment which is projected to have the rapid growth and having the major share.
This study implies the factors which are compelling and restricting the market growth and the providing pitfalls and opportunities for the Dystonia Drugs market.
This report also consists of information of the market’s leading vendors and their position in the market.
This report also consists of constant market developments and innovations taking place in the Dystonia Drugs market.
Dystonia Drugs Market by Drug Type
Anticonvulsants drugs
Others
Dopaminergic agents
GABAergic agents
Dystonia Drugs Market by Route of Administration
Oral
Injectable
Dystonia Drugs Market by Distribution Channel
Hospital Pharmacies
Online Providers
Drug Stores and Retail Pharmacies
Dystonia Drugs Market by Geography
North America
Europe
Asia Pacific
Rest of the World
The market based product type is divided into Anticonvulsants drugs, Others, Dopaminergic agents and GABAergic agents. GABAergic agents segment has the largest share in the market. The growth is ascribed to its advantages in treating dystonia, especially cervical dystonia. Moreover, the discovery of highly effective and potent GABAergic agent pharmaceuticals for treating dystonia, along with its more extensive prescription by healthcare experts, is boosting the segment's growth in the forecasted period.
As per the market by route of administration, the market is bifurcated into Oral and Injectable. Among them the injectable segment has the substantial share in the market. This is due to the increase in innovations in parenteral dosing and increased research and development for botulinum injections. Absorption of the medication, particularly aqueous solutions, is rapid and uniform. There is a swift commencement of effect compared to the oral and subcutaneous methods.
The distribution channel segment is classified into Hospital Pharmacies, Online Providers and Drug Stores and Retail Pharmacies. The drug stores & retail pharmacies segment is accounted for the maximum share in the market. This is because of its substantial chain of distribution networks and it being the oldest and most easy channel for providing drugs to consumers. Retail pharmacists prepare and dispense drugs, advise consumers on the proper use of medications, and inform them of possible drug interactions.
In market by geographical analysis, the North America region has acquired a substantial share in the market. The surge in incidences of dystonia coupled with surge in prevalence of other neurological conditions causing dystonia in U.S. population and other major nations is the key factor for augmenting demand for dystonia drugs in North America.
The federal government influences private investment on research and development through programs which augment the demand for prescription drugs, through policies (such as investment for basic research and regulations on what must be demonstrated in clinical trials) which affect the supply of new medicines, and through policies (such as vaccine recommendations) which affect both supply and demand. The surging R&D in the pharmaceutical industry worldwide is likely to improve the effectiveness of dystonia drugs and their utilization, thereby fueling the global market growth.
This report includes the key vendors operating in the market- Teva Pharmaceuticals Industries Ltd., F.Hoffmann-La Roche Ltd., Merz Pharma GmbH & Co. KGaA, Ipsen Pharma Biotech SAS, Hameln Pharma Gmbh (Siegfried Group, LLP), AbbVie, Inc., Amneal Pharmaceuticals, Inc., Wellona Pharma, Pfizer, Inc. and Novartis AG.
Henceforth, the dystonia drugs market is anticipated to witnessing a significant in the estimated time span. Since, compared to all treatments the drugs are considered to be the best option for the dystonia. The drugs are deemed to provide the quick and complete relief for the ailment.
This report of Dystonia Drugs market depicts the geographical regions and sub segment which is projected to have the rapid growth and having the major share.
This study implies the factors which are compelling and restricting the market growth and the providing pitfalls and opportunities for the Dystonia Drugs market.
This report also consists of information of the market’s leading vendors and their position in the market.
This report also consists of constant market developments and innovations taking place in the Dystonia Drugs market.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. DRUG TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Anticonvulsants drugs
5.3. Others
5.4. Dopaminergic agents
5.5. GABAergic agents
6. ROUTE OF ADMINISTRATION: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Oral
6.3. Injectable
7. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Hospital Pharmacies
7.3. Online Providers
7.4. Drug Stores and Retail Pharmacies
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. Teva Pharmaceuticals Industries Ltd.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. F.Hoffmann-La Roche Ltd.
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Merz Pharma GmbH & Co. KGaA
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Ipsen Pharma Biotech SAS
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Hameln Pharma Gmbh (Siegfried Group, LLP)
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. AbbVie, Inc.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Amneal Pharmaceuticals, Inc.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Wellona Pharma
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Pfizer, Inc.
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Novartis AG
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. DRUG TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Anticonvulsants drugs
5.3. Others
5.4. Dopaminergic agents
5.5. GABAergic agents
6. ROUTE OF ADMINISTRATION: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Oral
6.3. Injectable
7. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Hospital Pharmacies
7.3. Online Providers
7.4. Drug Stores and Retail Pharmacies
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. Teva Pharmaceuticals Industries Ltd.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. F.Hoffmann-La Roche Ltd.
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Merz Pharma GmbH & Co. KGaA
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Ipsen Pharma Biotech SAS
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Hameln Pharma Gmbh (Siegfried Group, LLP)
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. AbbVie, Inc.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Amneal Pharmaceuticals, Inc.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Wellona Pharma
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Pfizer, Inc.
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Novartis AG
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
LIST OF TABLES
TABLE 1. GLOBAL DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR ANTICONVULSANTS DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR DOPAMINERGIC AGENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR GABAERGIC AGENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR ORAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR INJECTABLE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR ONLINE PROVIDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR DRUG STORES AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA DYSTONIA DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 16. NORTH AMERICA DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 17. U.S DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 18. U.S DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 19. U.S DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 20. CANADA DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 21. CANADA DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 22. CANADA DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 23. EUROPE DYSTONIA DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 24. EUROPE DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 25. EUROPE DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 26. EUROPE DYSTONIA DRUGS MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 27. GERMANY DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 28. GERMANY DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 29. GERMANY DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 30. U.K DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 31. U.K DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 32. U.K DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 33. FRANCE DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 34. FRANCE DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 35. FRANCE DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 36. ITALY DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 37. ITALY DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 38. ITALY DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 39. SPAIN DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 40. SPAIN DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 41. SPAIN DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 42. ROE DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 43. ROE DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 44. ROE DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC DYSTONIA DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 48. ASIA PACIFC DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 49. CHINA DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 50. CHINA DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 51. CHINA DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 52. INDIA DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 53. INDIA DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 54. INDIA DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 55. JAPAN DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 56. JAPAN DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 57. JAPAN DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 60. REST OF APAC DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 63. REST OF WORLD DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 64. TEVA PHARMACEUTICALS INDUSTRIES LTD.: FINANCIALS
TABLE 65. TEVA PHARMACEUTICALS INDUSTRIES LTD.: PRODUCTS & SERVICES
TABLE 66. TEVA PHARMACEUTICALS INDUSTRIES LTD.: RECENT DEVELOPMENTS
TABLE 67. F.HOFFMANN-LA ROCHE LTD.: FINANCIALS
TABLE 68. F.HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES
TABLE 69. F.HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
TABLE 70. MERZ PHARMA GMBH & CO. KGAA: FINANCIALS
TABLE 71. MERZ PHARMA GMBH & CO. KGAA: PRODUCTS & SERVICES
TABLE 72. MERZ PHARMA GMBH & CO. KGAA: RECENT DEVELOPMENTS
TABLE 73. IPSEN PHARMA BIOTECH SAS: FINANCIALS
TABLE 74. IPSEN PHARMA BIOTECH SAS: PRODUCTS & SERVICES
TABLE 75. IPSEN PHARMA BIOTECH SAS: RECENT DEVELOPMENTS
TABLE 76. HAMELN PHARMA GMBH (SIEGFRIED GROUP, LLP): FINANCIALS
TABLE 77. HAMELN PHARMA GMBH (SIEGFRIED GROUP, LLP): PRODUCTS & SERVICES
TABLE 78. HAMELN PHARMA GMBH (SIEGFRIED GROUP, LLP): RECENT DEVELOPMENTS
TABLE 79. ABBVIE, INC.: FINANCIALS
TABLE 80. ABBVIE, INC.: PRODUCTS & SERVICES
TABLE 81. ABBVIE, INC.: RECENT DEVELOPMENTS
TABLE 82. AMNEAL PHARMACEUTICALS, INC.: FINANCIALS
TABLE 83. AMNEAL PHARMACEUTICALS, INC.: PRODUCTS & SERVICES
TABLE 84. AMNEAL PHARMACEUTICALS, INC.: RECENT DEVELOPMENTS
TABLE 85. WELLONA PHARMA: FINANCIALS
TABLE 86. WELLONA PHARMA: PRODUCTS & SERVICES
TABLE 87. WELLONA PHARMA: RECENT DEVELOPMENTS
TABLE 88. PFIZER, INC.: FINANCIALS
TABLE 89. PFIZER, INC.: PRODUCTS & SERVICES
TABLE 90. PFIZER, INC.: RECENT DEVELOPMENTS
TABLE 91. NOVARTIS AG: FINANCIALS
TABLE 92. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 93. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 1. GLOBAL DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR ANTICONVULSANTS DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR DOPAMINERGIC AGENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR GABAERGIC AGENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR ORAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR INJECTABLE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR ONLINE PROVIDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR DRUG STORES AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA DYSTONIA DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 16. NORTH AMERICA DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 17. U.S DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 18. U.S DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 19. U.S DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 20. CANADA DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 21. CANADA DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 22. CANADA DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 23. EUROPE DYSTONIA DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 24. EUROPE DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 25. EUROPE DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 26. EUROPE DYSTONIA DRUGS MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 27. GERMANY DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 28. GERMANY DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 29. GERMANY DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 30. U.K DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 31. U.K DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 32. U.K DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 33. FRANCE DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 34. FRANCE DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 35. FRANCE DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 36. ITALY DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 37. ITALY DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 38. ITALY DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 39. SPAIN DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 40. SPAIN DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 41. SPAIN DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 42. ROE DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 43. ROE DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 44. ROE DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC DYSTONIA DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 48. ASIA PACIFC DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 49. CHINA DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 50. CHINA DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 51. CHINA DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 52. INDIA DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 53. INDIA DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 54. INDIA DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 55. JAPAN DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 56. JAPAN DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 57. JAPAN DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 60. REST OF APAC DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 63. REST OF WORLD DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 64. TEVA PHARMACEUTICALS INDUSTRIES LTD.: FINANCIALS
TABLE 65. TEVA PHARMACEUTICALS INDUSTRIES LTD.: PRODUCTS & SERVICES
TABLE 66. TEVA PHARMACEUTICALS INDUSTRIES LTD.: RECENT DEVELOPMENTS
TABLE 67. F.HOFFMANN-LA ROCHE LTD.: FINANCIALS
TABLE 68. F.HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES
TABLE 69. F.HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
TABLE 70. MERZ PHARMA GMBH & CO. KGAA: FINANCIALS
TABLE 71. MERZ PHARMA GMBH & CO. KGAA: PRODUCTS & SERVICES
TABLE 72. MERZ PHARMA GMBH & CO. KGAA: RECENT DEVELOPMENTS
TABLE 73. IPSEN PHARMA BIOTECH SAS: FINANCIALS
TABLE 74. IPSEN PHARMA BIOTECH SAS: PRODUCTS & SERVICES
TABLE 75. IPSEN PHARMA BIOTECH SAS: RECENT DEVELOPMENTS
TABLE 76. HAMELN PHARMA GMBH (SIEGFRIED GROUP, LLP): FINANCIALS
TABLE 77. HAMELN PHARMA GMBH (SIEGFRIED GROUP, LLP): PRODUCTS & SERVICES
TABLE 78. HAMELN PHARMA GMBH (SIEGFRIED GROUP, LLP): RECENT DEVELOPMENTS
TABLE 79. ABBVIE, INC.: FINANCIALS
TABLE 80. ABBVIE, INC.: PRODUCTS & SERVICES
TABLE 81. ABBVIE, INC.: RECENT DEVELOPMENTS
TABLE 82. AMNEAL PHARMACEUTICALS, INC.: FINANCIALS
TABLE 83. AMNEAL PHARMACEUTICALS, INC.: PRODUCTS & SERVICES
TABLE 84. AMNEAL PHARMACEUTICALS, INC.: RECENT DEVELOPMENTS
TABLE 85. WELLONA PHARMA: FINANCIALS
TABLE 86. WELLONA PHARMA: PRODUCTS & SERVICES
TABLE 87. WELLONA PHARMA: RECENT DEVELOPMENTS
TABLE 88. PFIZER, INC.: FINANCIALS
TABLE 89. PFIZER, INC.: PRODUCTS & SERVICES
TABLE 90. PFIZER, INC.: RECENT DEVELOPMENTS
TABLE 91. NOVARTIS AG: FINANCIALS
TABLE 92. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 93. NOVARTIS AG: RECENT DEVELOPMENTS
